• LTR Pharma signs a binding term sheet with Shed Holdings LLC
• Establishes the first commercial route-to-market for ROXUS in the U.S.
• Minimum commercial volume target of 150,000 units in the first 12 months
• Two-year U.S. direct-to-consumer (DTC) telehealth exclusivity
• ROXUS to be supplied through the U.S. Section 503A personalised medicine pathway

LTR Pharma Limited has executed a binding term sheet with Shed Holdings LLC, a US direct-to-consumer (DTC) telehealth platform, to distribute ROXUS, LTR Pharma's personalized medicine treatment for erectile dysfunction, in the United States. This agreement establishes the first commercial route-to-market for ROXUS in the U.S., marking a significant step in LTR Pharma's commercialization strategy. Under the arrangement, LTR Pharma will be the product owner, intellectual property holder, and supplier, while Shed provides patient acquisition, telehealth, and commercial infrastructure. The binding term sheet includes a minimum commercial volume target of 150,000 ROXUS prescription units during the first 12 months from commercial launch and two-year U.S. DTC telehealth exclusivity, subject to performance requirements. The agreement is subject to the execution of Definitive Agreements within 60 days of the effective date.

LTR Pharma believes this framework positions ROXUS to become a leading intranasal treatment option within the rapidly growing U.S. men's health market.